LivaNova PLC (LIVN) shares surged 10.64% in pre-market trading on Wednesday following the release of better-than-expected first-quarter results and encouraging data from a clinical study on sleep apnea treatment.
The medical technology company reported Q1 revenue of $316.9 million, surpassing the IBES estimate of $302.3 million. Adjusted earnings per share came in at $0.88, significantly higher than the expected $0.76. LivaNova also raised its full-year 2025 revenue growth guidance to 6.0% to 7.0% on a constant-currency basis, up from the previous range of 5.0% to 6.0%.
Adding to the positive sentiment, LivaNova announced promising 12-month data from its OSPREY clinical study for moderate to severe obstructive sleep apnea. The study demonstrated strong response and durability of therapy, with an overall responder rate of 65% and a 68% reduction in both the median Apnea-Hypopnea Index and Oxygen Desaturation Index. These results, along with the company's recent premarket approval submission to the FDA for its aura6000 System, suggest potential future growth in the sleep apnea market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。